Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An overview from the research on adverse drug events and reports (RADAR) project

Leukemia Research

Volumn 31, Issue 5, 2007, Pages 599-604

  McKoy, June M ^e   Angelotta, Cara ^e   Bennett, Charles L ^a,b,e   Tallman, Martin S ^e   Wadleigh, Martha ^d   Evens, Andrew M ^e   Kuzel, Timothy M ^e   Trifilio, Steve M ^e   Raisch, Dennis W ^f   Kell, Jonathan ^g   DeAngelo, Daniel J ^d   Giles, Francis J ^c  

^a JESSE BROWN VA MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF NEW MEXICO   (United States)

^g UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Acute myeloid leukemia; Adverse drug reactions; Gemtuzumab ozogamicin; Sinusoidal obstructive syndrome; Stem cell transplantation

Indexed keywords

CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; INTERLEUKIN 11; MITOXANTRONE; RETINOIC ACID; TIOGUANINE; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ASCITES; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; DRUG SAFETY; HEPATOMEGALY; HUMAN; HYPERBILIRUBINEMIA; LIVER SINUSOID; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; WEIGHT GAIN;

ACUTE DISEASE; ADVERSE DRUG REACTION REPORTING SYSTEMS; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; IMMUNOTOXINS; INCIDENCE; LEUKEMIA, MYELOID; PROSPECTIVE STUDIES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34147197520     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.07.005     Document Type: Article

References (34)

1. Bross P.F., Beitz J., Chen G., et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7 (2001) 1490-1496
2. Larson R.A., Sievers E.L., Stadtmauer E.A., et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104 (2005) 1442-1452
3. Giles F.J., Kantarjian H.M., Kornblau S.M., et al. Gemtuzumab ozogamicin therapy is associated with hepatic veno-occlusive disease in patients who have not received stem cell transplantation. Cancer 92 (2001) 406-413
4. Rajvanshi P., Shulman H.M., Sievers E.L., and McDonald G.B. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin therapy. Blood 99 (2002) 2310-2314
5. Bennett C.L., Nebeker J.R., Lyons E.A., et al. The Research on Adverse Drug Events and Reports (RADAR) project. JAMA 293 (2005) 2131-2140
6. McDonald G.B. Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin. Clin Lymphoma 2S (2002) 35-39
7. Richardson P., and Guinan E. Hepatic veno-occlusive disease following hematopoietic stem cell transplantation. Acta Hemaetol 106 (2001) 57-68
8. Goldberg S., Ellent D., Shtrambrand D., et al. Prior allogeneic hematopoietic stem cell transplantation increases the risk of hepatic veno-occlusive disease. Blood 100 (2002) 1611a [abstract]
9. Giles F., Estey E., and O'Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer 98 (2003) 2095-2104
10. Kell W.J., Burnett A.K., Chopra R., et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 102 (2003) 4277-4283
11. Wadleigh M., Richardson P.G., Zahrieh D., et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 102 (2003) 1578-1582
12. Alvarado Y., Tsimberidou A., Kantarjian H., et al. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol 51 (2003) 87-90
13. Tallman M.S., Feingold J.M., Brown D.A., et al. Prospective observational study of Mylotarg in usual care: an update. Blood 102 (2003) 3258a
14. Mylotarg (gemtuzumab ozogamicin for injection). Philadelphia, PA: Wyeth Pharmaceuticals Inc.; 2006 [package insert].
15. Nabhan C., Rundhaugen L., Jatoi M., et al. Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease. Ann Oncol 15 (2004) 1231-1236
16. Tsimberidou A.-M., Giles F.J., Estey E., O'Brien S., Keating M.J., and Kantarjian H.M. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol 132 (2006) 398-409
17. Sievers E.L., Larson R.A., Stadtmauer E.A., et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19 (2001) 3244-3254
18. Bennett C.L., Nebeker J.R., Lyons E.A., et al. The Research on Adverse Drug Events and Reports (RADAR) project. JAMA 293 17 (2005) 2131-2140
19. Trontell A. Expecting the unexpected-drug safety, pharmacovigilance, and the prepared mind. N Engl J Med 351 14 (2004) 1385-1387
20. Trontell A.E. The RADAR project and the FDA. JAMA 294 10 (2005) 1206 [author reply 1206-7]
21. Wood A.J.J. Thrombotic thrombocytopenic purpura and clopidogrel. A need for new approaches to drug safety. N Engl J Med 342 (2000) 1824-1826 [editorial]
22. Cohen A.D., Luger S.M., Sickles C., et al. Gemtuzumab ozogamicin monotherapy for relapsed AML after hemopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplant 30 (2002) 23-29
23. Areci R.J., Sande J., Lange B., et al. Safety and efficacy of gemtuzumab ozogamycin in patients with advanced CD33+ acute myeloid leukemia. Blood 106 (2005) 1183-1188
24. Apostolidou E., Cortes J., Tsimberidou A., et al. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine, and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leukemia Res 27 (2003) 887-891
25. DeAngelo D.J., Stone R.M., and Durrant D. Gemtuzumab ozogamicin in combination with induction chemotherapy for the treatment of patients with de novo acute myeloid leukemia: two age-specific phase 2 trials. Blood 102 (2003) 341a [abstract]
26. Tsimberidou A., Cortes J., Thomas D., et al. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leukemia Res 27 (2003) 893-897
27. Tsimberidou A., Estey E., Cortes J., et al. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 97 (2003) 1481-1487
28. Tsimberidou A.M., Estey E., Cortes J.E., et al. Mylotarg, fludarabine, cytarabine, and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol 52 (2003) 449-452
29. Estey E.H., Giles F.J., Beran M., et al. Experience with gemtuzumab ozogamycin and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 99 (2002) 4222-4224
30. Langston A., Feinstein B., Hutcherson D., et al. Non-fatal veno-occlusive disease in non-transplant patients after treatment of relapsed AML with gemtuzumab ozogamicin. Blood 99 (2001) 4510a [abstract]
31. Zwaan C.M., Reinhardt D., Corbacioglu S., et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood 101 (2003) 3868-3871
32. Cortes J., Tsimberidou A., Alvarez R., et al. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Pharmacol 50 (2002) 497-500
33. Castaigne S., Raffoux R., Bastie J.N., et al. Fractionated low-doses of Mylotarg in relapsed AML patients: a pilot study. Blood 100 (2002) 3036a [abstract]
34. Jiang Y., Kantarjian H.M., Faderl S.H., Cortes J., Koller K., and Estey E. Follow-up of gemtuzumab ozogamicin and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 102 (2003) 2284a [abstract]